Eli Lilly’s Next-Gen Obesity Drug Shows Promising Trial Results in Race Beyond Ozempic

Retatrutide is being called a “triple G” obesity drug because it targets three different gut hormones involved in appetite, metabolism, and blood sugar regulation: GLP-1, GIP, and glucagon. Current drugs…

Continue ReadingEli Lilly’s Next-Gen Obesity Drug Shows Promising Trial Results in Race Beyond Ozempic